SecurityDBOEY / Deutsche Boerse AG (251542106)
Institutional Owners104 (96 N-Q Owners)
Institutional Shares1,957,344 (ex. N-Q)
Institutional Value$ 26,664,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

DBOEY / Deutsche Boerse AG Institutional Ownership

Deutsche Boerse AG (OTC:DBOEY) has 104 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,957,344 shares. Largest shareholders include Parametric Portfolio Associates Llc, Fisher Asset Management, LLC, Genesee Valley Trust Co, Canandaigua National Bank & Trust Co, Pnc Financial Services Group, Inc., Private Capital Group, Llc, Glenmede Trust Co Na, and Quadrant Capital Group Llc.
Deutsche Boerse AG (OTC:DBOEY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="DBOEY / Deutsche Boerse AG Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-21 N-Q M Fund Inc (see advisory)
2018-05-22 N-Q Master Investment Portfolio (see advisory)
2018-05-22 N-Q Transamerica Series Trust (see advisory)
2018-02-28 N-Q Prudential Investment Portfolios, Inc. (see advisory)
2018-05-10 13F-HR QUADRANT CAPITAL GROUP LLC 975 975 0.00 9 11 22.22
2018-03-29 N-Q Advisors' Inner Circle Fund (see advisory)
2018-05-21 13F-HR Mcilrath & Eck, Llc 57 0 -100.00 1 0 -100.00
2018-04-02 N-Q John Hancock Exchange-traded Fund Trust (see advisory)
2018-02-28 N-Q Morgan Stanley Institutional Fund Trust (see advisory)
2018-04-27 N-Q Trust For Professional Managers (see advisory)
2018-03-23 N-Q Alpine Global Dynamic Dividend Fund (see advisory)
2018-03-27 N-Q Transamerica Funds (see advisory)
2017-12-29 N-Q Nuveen Investment Trust V (see advisory)
2018-03-16 N-Q Horizons Etf Trust I (see advisory)
2018-05-22 N-Q Transamerica Etf Trust (see advisory)
2018-04-24 N-Q American Century Strategic Asset Allocations Inc (see advisory)
2018-05-15 13F-HR GLENMEDE TRUST CO NA 1,880 1,880 0.00 21 21 0.00
2018-05-17 N-Q Baillie Gifford Funds (see advisory)
2018-04-02 N-Q Dunham Funds (see advisory)
2018-01-29 N-Q Goldman Sachs Etf Trust (see advisory)
2018-03-23 N-Q Alpine Series Trust (see advisory)
2018-04-26 N-Q Exchange Traded Concepts Trust (see advisory)
2018-02-27 N-Q Touchstone Strategic Trust (see advisory)
2018-05-16 13F-HR Private Capital Group, Llc 1,284 2,906 126.32 15 40 166.67
2018-03-26 N-Q Mfs Series Trust Vi (see advisory)
2018-05-22 N-Q Blackrock Advantage Global Fund, Inc. (see advisory)
2018-04-24 N-Q American Century World Mutual Funds Inc (see advisory)
2018-05-15 N-Q Russell Investment Funds (see advisory)
2018-02-28 N-Q Ivy Funds (see advisory)
2018-05-21 N-Q Mfs Variable Insurance Trust (see advisory)
2018-03-29 N-Q Russell Investment Co (see advisory)
2018-03-19 N-Q TIAA-CREF FUNDS (see advisory)
2018-03-27 N-Q Reality Shares Etf Trust (see advisory)
2018-03-27 N-Q Schwab Capital Trust (see advisory)
2018-03-27 N-Q Nationwide Mutual Funds (see advisory)
2018-05-22 N-Q Blackrock Funds Iii (see advisory)
2018-02-28 N-Q Ishares Trust (see advisory)
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 5,780 5,754 -0.45 67 78 16.42
2018-04-16 13F-HR Ledyard National Bank 61 0 -100.00 1 0 -100.00
2018-03-23 N-Q Pacer Funds Trust (see advisory)
2018-03-28 N-Q Voya Mutual Funds (see advisory)
2018-04-26 N-Q Federated World Investment Series Inc (see advisory)
2018-01-18 N-Q Etf Series Solutions (see advisory)
2018-03-01 N-Q Aqr Funds (see advisory)
2018-03-01 N-Q Sei Institutional International Trust (see advisory)
2018-05-11 N-Q Neuberger Berman Advisers Management Trust (see advisory)
2017-12-28 N-Q Franklin Global Trust (see advisory)
2018-03-01 N-Q Spdr Index Shares Funds (formerly Streettracks Index Shares Funds) (see advisory)
2018-01-26 N-Q Voya International High Dividend Equity Income Fund (see advisory)
2018-02-28 N-Q VANGUARD HORIZON FUNDS (see advisory)
2018-04-24 N-Q Dbx Etf Trust (see advisory)
2018-03-27 N-Q Prudential Investment Portfolios 2 (see advisory)
2018-03-28 N-Q Bbh Trust (see advisory)
2018-02-27 N-Q Massmutual Select Funds (see advisory)
2018-01-24 N-Q Blackrock Funds (see advisory)
2018-03-29 N-Q Vanguard Charlotte Funds (see advisory)
2018-01-26 N-Q Eaton Vance Growth Trust (see advisory)
2018-02-28 N-Q Gps Funds I (see advisory)
2018-03-29 N-Q Aim International Mutual Funds (invesco International Mutual Funds) (see advisory)
2018-05-18 N-Q State Farm Variable Product Trust (see advisory)
2018-02-28 N-Q Franklin Templeton Etf Trust (see advisory)
2018-03-27 N-Q Schwab Investments (see advisory)
2018-05-22 N-Q Blackrock Index Funds, Inc. (see advisory)
2018-03-28 N-Q Old Westbury Funds Inc (see advisory)
2018-03-29 N-Q Goldman Sachs Trust Ii (see advisory)
2018-03-27 N-Q Indexiq Etf Trust (see advisory)
2018-01-23 N-Q Schwab Strategic Trust (see advisory)
2017-12-29 N-Q Adviser Managed Trust (see advisory)
2018-02-28 N-Q Wisdomtree Trust (see advisory)
2018-04-27 N-Q Ab Global Risk Allocation Fund, Inc. (see advisory)
2018-03-26 N-Q Legg Mason Etf Investment Trust (see advisory)
2018-03-01 N-Q Janus Investment Fund (see advisory)
2018-03-01 N-Q Calvert Responsible Index Series, Inc. (see advisory)
2018-03-23 N-Q Alpine Total Dynamic Dividend Fund (see advisory)
2018-05-18 N-Q State Farm Mutual Fund Trust (see advisory)
2018-05-17 N-Q Guardian Variable Products Trust (see advisory)
2018-05-22 N-Q Quantitative Master Series Llc (see advisory)
2018-02-27 N-Q Artisan Partners Funds Inc (see advisory)
2018-03-29 N-Q Powershares Exchange-traded Fund Trust Ii (see advisory)
2018-04-27 N-Q Usaa Mutual Funds Trust (see advisory)
2018-04-27 N-Q Valic Co I (see advisory)
2018-03-29 N-Q Jpmorgan Trust Ii (see advisory)
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 1,711,491 1,882,061 9.97 19,742 25,652 29.94
2018-05-15 N-Q Bridge Builder Trust (see advisory)
2018-03-28 N-Q J.p. Morgan Exchange-traded Fund Trust (see advisory)
2018-04-03 13F-HR GENESEE VALLEY TRUST CO 21,663 21,618 -0.21 252 289 14.68
2018-03-29 N-Q Winton Diversified Opportunities Fund (see advisory)
2018-04-27 N-Q Wells Fargo Master Trust (see advisory)
2018-02-28 N-Q Seasons Series Trust (see advisory)
2018-03-01 N-Q Sei Institutional Managed Trust (see advisory)
2018-03-29 N-Q Advisors' Inner Circle Fund Iii (see advisory)
2018-03-29 N-Q Vanguard Star Funds (see advisory)
2018-02-27 N-Q Thornburg Investment Trust (see advisory)
2018-03-22 N-Q Dreyfus Index Funds Inc (see advisory)
2018-03-29 N-Q Vanguard International Equity Index Funds (see advisory)
2018-03-27 N-Q PRINCIPAL FUNDS INC (see advisory)
2018-04-25 N-Q Federated Global Allocation Fund (see advisory)
2018-04-20 13F-HR/A Fisher Asset Management, LLC 24,635 335
2018-03-27 N-Q Harbor Funds (see advisory)
2018-03-29 N-Q Flexshares Trust (see advisory)
2018-03-29 N-Q Eaton Vance Mutual Funds Trust (see advisory)
2018-03-27 N-Q Wells Fargo Funds Trust (see advisory)
2018-03-29 N-Q Tax-managed International Equity Portfolio (see advisory)
2018-03-29 N-Q Jpmorgan Trust I (see advisory)
2018-02-09 N-Q Ariel Investment Trust (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( DBOEY / Deutsche Boerse AG ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Deutsche Boerse to include tech stocks in MDAX and SDAX in index shakeup

2018-05-19 reuters
FRANKFURT (Reuters) - Deutsche Boerse, the German stock exchange operator, is planning a major shakeup of the composition of three key indexes later this year that affects technology stocks. (2-0)

Singapore's China-Backed Exchange Set to Start Trading on May 25 - Bloomberg

2018-05-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (9-0)

Deutsche Borse (DBOEY) Investor Presentation - Slideshow

2018-05-17 seekingalpha
The following slide deck was published by Deutsche Boerse AG ADR in conjunction with this event. (1-0)

German bourse to cut 50 managerial jobs

The German exchange group’s chief executive officer told shareholders yesterday that he wants to cut as many as 50 management jobs as part of a plan to lower its annual running costs by €100mil (US$118mil) by the end of 2020. (2-0)

Deutsche Boerse to Cut as Many as 50 Management Positions - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

CUSIP: 251542106